FDA Yields To Pressure, Delays ‘Intended Use’ Rule
The agency has granted a petition from trade groups to delay controversial revisions to its definition of “intended use” for at least one year, and is also gathering comments to guide possible further revisions.
You may also be interested in...
After much wrangling, the US agency finally clarified its position on what evidence can determine "intended use" of a product – and industry is not happy.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.
US FDA Chief Counsel Rebecca Wood discussed ongoing reforms to FDA’s free speech enforcement approach and other enforcement priorities at a recent conference.